Rethink is now calling on the Ontario government to complete and implement the new evidence-building program guidelines as scheduled. "We urge the government to be transparent and stick closely to their timelines in the creation of this program," said DeCoteau. "Rethink is committed to working with the government on this initiative, and asks that we are brought to the table as soon as possible so that the voice of the patient is heard."

Rethink believes in equal access to optimal treatment for all women living with breast cancer in Canada. Over the past two weeks, Rethink has advocated for equal and timely access to Herceptin for women with HER2-positive tumours less than 1 cm. Speaking out to the media regarding the inequality in access to treatment across Canada, Rethink also started a letter writing campaign on their website, www.rethinkbreastcancer, and encouraged the public to support women like Jill by speaking out against this issue and demonstrating a need for policy change. To date, more than 4,000 people clicked on the link to send a letter to Health Minister Deb Matthews.

Source: RETHINK BREAST CANCER